Healthcare/Neuroscience Analysts, along with Dr. Anton Porsteinsson, in conjunction with Needham’s Virtual Neuroscience Forum and provide a commercial update of BIIB‘s Leqembi, discuss the upcoming TRAILBLAZER-ALZ 2 data readout for LLY‘s donanemab on an Analyst/Industry conference call to be held on March 15 at 12:15 pm.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BIIB:
- No ad com suggests positive potential outcome for Sage’s zura, says BofA
- Biogen elects Dorsa as Chair of the Board of Directors
- Caroline Dorsa to Succeed Stelios Papadopoulos as Chair of Biogen Board of Directors
- Biogen, Sage Therapeutics: FDA has no plans to discuss NDA for zuranolone
- Eisai, Biogen say FDA accepted sBLA for LEQEMBI, granted Priority Review
